scholarly journals Hepatitis E Virus Seroprevalence Among Liver Transplant Recipients with Persistent Elevation of Liver Enzymes: A Single Center Report

2021 ◽  
Vol 24 (1) ◽  
pp. 22-26
Author(s):  
Maryam Chorami ◽  
Kamran Bagheri Lankarani ◽  
Fardad Ejtehadi ◽  
Seyed Ali Malek-Hosseini ◽  
Maryam Moini
Keyword(s):  
Chronic Hepatitis ◽  
Liver Transplant ◽  
Hepatitis E Virus ◽  
Liver Enzymes ◽  
Organ Transplant ◽  
Hepatitis E ◽  
Solid Organ ◽  
Transplant Recipients ◽  
Liver Transplant Recipients ◽  
Persistent Elevation

Background: Chronic hepatitis E infection has been reported in solid organ transplant recipients following acute hepatitis due to the compromised immune status. Almost all reports are from areas where hepatitis E virus (HEV) genotypes 3 and 4 are the dominant genotypes. This study was conducted to investigate the role of hepatitis E infection as an etiology for liver enzymes elevation in liver transplant recipients from the largest liver transplant program in Iran. Methods: In a prospective study from June to December 2015, in a single liver transplantation center in Iran, all adult liver recipients who were investigated for the etiology of persistent elevation of liver enzymes were tested for HEV serology status. Results: Of 122 patients included in the study, 19 (15.6%) were positive for HEV serology. Seropositive patients were significantly older than seronegative ones (mean age 43.79 vs. 31.58, P < 0.001); however, they were not different in other characteristics including sex distribution and mean of liver enzymes in each occasion. Liver biopsies were done in 16 HEV seropositive patients and none of the biopsies showed evidence for acute or chronic viral hepatitis. Conclusion: In this study, with 15.6% rate of HEV seropositivity in liver recipients with persistent elevation of liver enzymes, we were not able to confirm any clinical evidence for active acute or chronic hepatitis E infection. This could theoretically be attributed to the fact that the dominant prevalent HEV genotype in our endemic area is not associated with a chronic form of infection.

scholarly journals Chronic hepatitis E virus infection in liver transplant recipients

2008 ◽  
Vol 14 (4) ◽  
pp. 547-553 ◽  
Author(s):  
Elizabeth B. Haagsma ◽  
Arie P. van den Berg ◽  
Robert J. Porte ◽  
Cornelis A. Benne ◽  
Harry Vennema ◽  
...  
Keyword(s):  
Chronic Hepatitis ◽  
Virus Infection ◽  
Liver Transplant ◽  
Hepatitis E Virus ◽  
Hepatitis E ◽  
Transplant Recipients ◽  
Liver Transplant Recipients

scholarly journals Sofosbuvir Add-on to Ribavirin Treatment for Chronic Hepatitis E Virus Infection in Solid Organ Transplant Recipients Does Not Result in Sustained Virological Response

2019 ◽  
Vol 6 (8) ◽  
Author(s):  
E M van Wezel ◽  
J de Bruijne ◽  
K Damman ◽  
M Bijmolen ◽  
A P van den Berg ◽  
...  
Keyword(s):  
Chronic Hepatitis ◽  
Virus Infection ◽  
Hepatitis E Virus ◽  
Organ Transplant ◽  
Hepatitis E ◽  
Solid Organ Transplant ◽  
Solid Organ ◽  
Transplant Recipients ◽  
Organ Transplant Recipients ◽  
Solid Organ Transplant Recipients

Abstract Ribavirin is effective for treating immunocompromised patients with chronic hepatitis E virus infection. However, ribavirin treatment is not always successful. We describe 3 solid organ transplant recipients treated with sofosbuvir and ribavirin after failing ribavirin monotherapy. Complete elimination of hepatitis E virus could not be achieved.

scholarly journals A Nationwide Survey of Hepatitis E Virus Infection and Chronic Hepatitis E in Liver Transplant Recipients in Japan

EBioMedicine ◽  
2015 ◽  
Vol 2 (11) ◽  
pp. 1607-1612 ◽  
Author(s):  
Yuki Inagaki ◽  
Yukio Oshiro ◽  
Tomohiro Tanaka ◽  
Tomoharu Yoshizumi ◽  
Hideaki Okajima ◽  
...  
Keyword(s):  
Chronic Hepatitis ◽  
Virus Infection ◽  
Liver Transplant ◽  
Hepatitis E Virus ◽  
Nationwide Survey ◽  
Hepatitis E ◽  
Transplant Recipients ◽  
Liver Transplant Recipients

scholarly journals Hepatitis E Virus Infection among Solid Organ Transplant Recipients, the Netherlands

2012 ◽  
Vol 18 (5) ◽  
pp. 869-872 ◽  
Author(s):  
Suzan D. Pas ◽  
Rob A. de Man ◽  
Claudia Mulders ◽  
Aggie H.M.M. Balk ◽  
Peter T.W. van Hal ◽  
...  
Keyword(s):  
Virus Infection ◽  
The Netherlands ◽  
Hepatitis E Virus ◽  
Organ Transplant ◽  
Hepatitis E ◽  
Solid Organ Transplant ◽  
Solid Organ ◽  
Transplant Recipients ◽  
Organ Transplant Recipients ◽  
Solid Organ Transplant Recipients

Hepatitis E virus-associated cryoglobulinemia in solid-organ-transplant recipients

2018 ◽  
Vol 38 (12) ◽  
pp. 2178-2189 ◽  
Author(s):  
Olivier Marion ◽  
Florence Abravanel ◽  
Arnaud Del Bello ◽  
Laure Esposito ◽  
Sebastien Lhomme ◽  
...  
Keyword(s):  
Hepatitis E Virus ◽  
Organ Transplant ◽  
Hepatitis E ◽  
Solid Organ Transplant ◽  
Solid Organ ◽  
Transplant Recipients ◽  
Organ Transplant Recipients ◽  
Solid Organ Transplant Recipients

Ribavirin for Hepatitis E Virus Infection After Organ Transplantation: A Large European Retrospective Multicenter Study

2019 ◽  
Vol 71 (5) ◽  
pp. 1204-1211 ◽  
Author(s):  
Nassim Kamar ◽  
Florence Abravanel ◽  
Patrick Behrendt ◽  
Jörg Hofmann ◽  
Georges Phillippe Pageaux ◽  
...  
Keyword(s):  
Chronic Hepatitis ◽  
Retrospective Study ◽  
Multicenter Study ◽  
Virological Response ◽  
Hepatitis E Virus ◽  
Large Scale ◽  
Organ Transplant ◽  
Hepatitis E ◽  
Solid Organ Transplant ◽  
Solid Organ

Abstract Background Ribavirin is currently recommended for treating chronic hepatitis E virus (HEV) infection. This retrospective European multicenter study aimed to assess the sustained virological response (SVR) in a large cohort of solid organ transplant (SOT) recipients with chronic HEV infection treated with ribavirin monotherapy (N = 255), to identify the predictive factors for SVR, and to evaluate the impact of HEV RNA mutations on virological response. Methods Data from 255 SOT recipients with chronic HEV infection from 30 European centers were analyzed. Ribavirin was given at the median dose of 600 (range, 29–1200) mg/day (mean, 8.6 ± 3.6 mg/kg/day) for a median duration of 3 (range, 0.25–18) months. Results After a first course of ribavirin, the SVR rate was 81.2%. It increased to 89.8% when some patients were offered a second course of ribavirin. An increased lymphocyte count at the initiation of therapy was a predictive factor for SVR, while poor hematological tolerance of ribavirin requiring its dose reduction (28%) and blood transfusion (15.7%) were associated with more relapse after ribavirin cessation. Pretreatment HEV polymerase mutations and de novo mutations under ribavirin did not have a negative impact on HEV clearance. Anemia was the main adverse event. Conclusions This large-scale retrospective study confirms that ribavirin is highly efficient for treating chronic HEV infection in SOT recipients and shows that the predominant HEV RNA polymerase mutations found in this study do not affect the rate of HEV clearance. This large-scale retrospective study that included 255 solid organ transplant recipients confirms that ribavirin is highly efficient for treating chronic hepatitis E virus (HEV) infection and shows that HEV RNA polymerase mutations do not play a role in HEV clearance.

Sign in / Sign up

Export Citation Format

Share Document